Alofisel®▼ (darvadstrocel) Administration Method

Alofisel® is indicated for the treatment of complex perinal fistulae in adult patients with nonactive/mildly active luminal Crohn's disease, when fistulae have shown an inadequate response to at least one conventional or biologic therapy (1).  Alofisel should be used after conditioning of fistula.  The below video details the Alofisel® administration method and is provided as part of the product's risk management plan.

View the Alofisel® 5 million cells/mL suspension for injection SmPC & PIL

 

 

Ref 1. Alofisel®▼Summary of Product Characteristics, Takeda UK Limited. Available from www.medicines.org.uk. Last accessed July 2018

 

 

 

UK/CX6/1807/0041

Date of Preparation: July 2018

The information contained within the Healthcare Professional section of this website is intended for UK healthcare professionals and may contain promotional information on Takeda products.

Please click CONTINUE to confirm that you are a UK healthcare professional.
Click CANCEL to navigate to other sections of the website.

CONTINUE CANCEL

Copyright 1995-2020 Takeda Pharmaceutical Company Limited. All rights reserved.

You are about to leave the Takeda UK website. Do you wish to proceed?

Takeda UK makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda UK does not recommend and does not endorse the content on any third party websites. Your use of third party websites is at your own risk and subject to the terms and conditions of use for such sites.

You are about to leave the Takeda UK website. Do you wish to proceed?

Takeda UK makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda UK does not recommend and does not endorse the content on any third party websites. Your use of third party websites is at your own risk and subject to the terms and conditions of use for such sites.